A common component of the contraceptive pill (progesterone) could improve the neurologic outcome for patients with severe head injuries, according to a study published in BioMed Central's open access journal Critical Care.
Traumatic brain injury (TBI), such as that caused by traffic accidents, falls and sporting injuries, is a major cause of death and disability. A number of 'neuroprotective' drugs have been shown to prevent nerve-cell death in animal models of traumatic brain injury, but these findings have not been translated into trials involving people with head injuries.
Progesterone is a female hormone used in the oral contraceptive pill. Preliminary animal and human studies suggest that progesterone could be a useful and safe way to treat acute severe traumatic brain injury, but its neuroprotective effects are unclear. Now, Chinese researchers have shown that progesterone can improve the neurologic outcome of patients with this kind of brain injury for up to six months.
A research team from Hangzhou Normal University and Zhejiang University in Hangzhou, supervised by Professor Weiqi Yan, studied 159 patients with acute traumatic brain injury admitted to a single hospital. In this randomized, double-blinded trial approximately half the patients received progesterone and the other half placebo for five days after brain injury.
"Although previous studies in animal suggest that progesterone may mitigate the severity of brain damage, there is no information about therapeutic benefit of post-TBI progesterone injections in the patients with severe brain trauma" said Professor Yan. "Our work was to determine if progesterone improve chances for recovery in patients with severe injuries in a longer-term".
Patient outcomes were classified either as favourable (good recovery or moderate disability) or unfavourable (severe disability, vegetative state or death). Neurological outcomes were measured using the Glasgow Outcome Scale, a medical system for evaluating the functional outcome of patients.
At both three and six months after treatment, significantly more patients given progesterone had favourable outcomes compared to patients given placebo. Progesterone was also linked to increased survival at six months. No complications or adverse events were seen in the patients given progesterone.
"We found encouraging evidence that progesterone may significantly improve 6-month neurologic outcome of the patients who were enrolled with acute severe TBI" according to lead author, Dr Giomin Xiao. "Our results provide information important for further multicenter clinical trials on progesterone as a promising neuroprotective drug".
Notes to Editors:
1. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial
Guomin Xiao, Jing Wei, Weiqi Yan, Weimin Wang and Zhenhui Lu
Critical Care (in press)
During embargo, article available here:
After the embargo, article available at the journal website:
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication.
2. Critical Care is a high quality, peer-reviewed, international clinical medical journal. Critical Care aims to improve the care of critically ill patients by acquiring, discussing, distributing, and promoting evidence-based information relevant to intensivists. The journal is edited by Prof Jean-Louis Vincent (Belgium) and has an Impact Factor of 3.12
3. BioMed Central (http://www.